Skip to main content

Table 1 The distribution of various cancers of the lung among the patients and the treatment regimens they received

From: Shifts in subsets of CD8+ T-cells as evidence of immunosenescence in patients with cancers affecting the lungs: an observational case-control study

Sex Subtype 1 Subtype 2 Stage Treatment (N) N N N N
T0 T1 T3 T6
Male SCLC   IIIA CE + R (1) 1 1 1 0
  SCLC   IIIB CE + R (1) 1 1 1 1
  SCLC   IV CE (1) 1 1 1 1
  MM   IV CP (2) 2 2 2 1
  NSCLC NSCC IIIA CD + R (1) 1 1 1 1
   NSCC IV CD + R (1), CP (11)a 12 12 10 8
   SCC IIIB CD + R (1), CG (1) 2 2 2 2
Female NSCLC NSCC IIIA CV (1) 1 1 1 1
   NSCC IIIB CP (1) 1 1 1 0
   NSCC IV CP (2) 2 2 2 2
  1. Lung cancer: SCLC small cell lung cancer, MM mesothelioma of the lung, NSCLC non-small cell lung cancer, SCC squamous cell carcinoma of the lung, and NSCC Non squamous cell carcinoma
  2. Treatment: CD cisplatin & docetaxel, CE cisplatin & etoposide, CG cisplatin & gemcitabine, CP cisplatin & pemetrexed, CV cisplatin & vinorelbine, R radiotherapy
  3. N Number of recipients for a particular chemotherapy regimen
  4. aThe number of participants reduced to 10 and 8 at the 3rd and 6th months respectively